Johnson & Johnson Eyes Acquisition of Ollin Biosciences for Up to $3.4 Billion
18 hours ago
Johnson & Johnson is reportedly set to acquire Texas-based biotech Ollin Biosciences for up to $3.4 billion to expand its ophthalmology portfolio. The deal centers on OLN324, an experimental drug for diabetic macular edema and age-related macular degeneration.